Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
ACOR Price Action
ACOR RSI Chart
ACOR Valuation
ACOR Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
ACOR Fundamentals
ACOR Revenue
ACOR Earnings
ACOR Profitability
ACOR Investor Care
Revenue & Growth
Revenue Breakdown
As of: Mar 31, 2024
Product
| |||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2024 | 115.7M | 0 | 0 | 0 |
| 2023 | 118.3M | 116.9M | 111.1M | 117.6M |
| 2022 | 122.7M | 122.0M | 124.1M | 118.6M |
| 2021 | 153.7M | 151.9M | 130.3M | 129.1M |
| 2020 | 176.4M | 159.9M | 165.3M | 153.0M |
| 2019 | 409.4M | 306.2M | 211.1M | 192.4M |
| 2018 | 575.1M | 588.9M | 590.7M | 471.4M |
| 2017 | 523.1M | 535.1M | 540.5M | 588.3M |
| 2016 | 508.7M | 522.5M | 509.9M | 519.6M |
| 2015 | 420.8M | 437.4M | 479.6M | 492.7M |
| 2014 | 345.1M | 355.2M | 376.2M | 401.5M |
| 2013 | 306.4M | 317.8M | 325.3M | 336.4M |
| 2012 | 302.2M | 312.6M | 297.0M | 305.8M |
| 2011 | 235.1M | 256.9M | 286.3M | 292.2M |
| 2010 | 57.3M | 86.0M | 135.2M | 191.1M |
| 2009 | 0 | 53.8M | 54.2M | 54.7M |
| 2008 | 0 | 0 | 0 | 53.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.
| CEO | Dr. Ron Cohen M.D. |
|---|---|
| WEBSITE | acorda.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers Specialty & Generic |
| EMPLOYEES | 111 |
